

October 21, 2020  
Announcement no. 20

## Managers' transactions

In connection with the completion of BioPorto A/S' rights issue as described in company announcement no. 19, BioPorto has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons with managerial responsibilities in BioPorto A/S and/or persons closely related with them.

<b>1. Details of the person discharging managerial responsibilities/person closely associated</b>	
a) Name	Christopher James Lindop
<b>2. Reason for the notification</b>	
a) Position/status	Member of the Board of Directors of BioPorto A/S
b) Initial notification/amendment	Initial notification
<b>3. Details of the issuer</b>	
a) Name	BioPorto A/S
b) LEI	5299004SWFL5JAN4W830
<b>4. Details of the transaction(s)</b>	
a) Description of the financial instrument, type of instrument	Shares
Identification code	ISIN code DK0061409042 to be merged with permanent ISIN code DKDK0011048619, expectedly no later than on 21 October 2020
b) Nature of the transaction	Purchase (exercise of subscription rights in connection with rights issue)
c) Price(s) and volume(s)	Price: DKK 1.6, Volume: 111,621
d) Aggregated information	N/A
- Aggregated volume	
- Aggregated price	
e) Date of the transaction	2020-10-21 8.30 a.m. UTC (10:30 a.m. CEST)
f) Place of the transaction	Nasdaq Copenhagen A/S, XCSE

---

**1. Details of the person discharging managerial responsibilities/person closely associated**


---

a) Name Ole Larsen

---

**2. Reason for the notification**


---

a) Position/status Chief Financial Officer of BioPorto A/S

---

b) Initial notification/amendment Initial notification

---

**3. Details of the issuer**


---

a) Name BioPorto A/S

---

b) LEI 5299004SWFL5JAN4W830

---

**4. Details of the transaction(s)**


---

a) Description of the financial instrument, type of instrument Shares

Identification code ISIN code DK0061409042 to be merged with permanent ISIN code DKDK0011048619, expectedly no later than on 21 October 2020

---

b) Nature of the transaction Purchase (exercise of subscription rights in connection with rights issue)

---

c) Price(s) and volume(s) Price: DKK 1.6, Volume: 108,468

---

d) Aggregated information N/A

- Aggregated volume
- Aggregated price

---

e) Date of the transaction 2020-10-21 8.30 a.m. UTC (10:30 a.m. CEST)

---

f) Place of the transaction Nasdaq Copenhagen A/S, XCSE

---



---

**1. Details of the person discharging managerial responsibilities/person closely associated**


---

a) Name Therazone ApS

---

**2. Reason for the notification**


---

a) Position/status Closely associated person to Thomas Magnussen, Chairman of the Board of Directors of BioPorto A/S

---

b) Initial notification/amendment Initial notification

---

---

### 3. Details of the issuer

---

a) Name	BioPorto A/S
b) LEI	5299004SWFL5JAN4W830

---

### 4. Details of the transaction(s)

---

a) Description of the financial instrument, type of instrument	Shares
Identification code	ISIN code DK0061409042 to be merged with permanent ISIN code DKDK0011048619, expectedly no later than on 21 October 2020
b) Nature of the transaction	Purchase (exercise of subscription rights in connection with rights issue)
c) Price(s) and volume(s)	Price: DKK 1.6, Volume: 311,220
d) Aggregated information <ul style="list-style-type: none"><li>- Aggregated volume</li><li>- Aggregated price</li></ul>	N/A
e) Date of the transaction	2020-10-21 8.30 a.m. UTC (10:30 a.m. CEST)
f) Place of the transaction	Nasdaq Copenhagen A/S, XCSE

---

***For further information, please contact:***

Peter Mørch Eriksen, CEO  
Ole Larsen, CFO  
Telephone +45 4529 0000, e-mail: [investor@bioporto.com](mailto:investor@bioporto.com)

***About BioPorto***

*BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients' lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].*